He Ministry of Health and Social Protectionin the face of the availability of insulins in the country, he said Friday that there are currently only problems with the crystalline and isopaneous human insulinwhich, according to the portfolio, have begun to solve.
“(…) The other types of insulin, known as analogues, maintain a stable marketing in the national territory“He complemented.
(Further: ‘Anguish’: health sector urges the national government to solve its situation).
Within the framework of its supply monitoring, the Ministry reported that it was possible to identify that human insulins (crystalline and isopane) were declared as medications “unfit“For him Invima.
Insulin
Mayor’s Office of Bogotá
It is worth mentioning that, although in Colombia there are four health registration holders (Pisa Pharmaceutical, Elyxim Biopharmaceutical, Biocon and Novo Nordisk), currently Only Pisa Pharmaceutical markets these products due to the loss of commercial interest of the other three holders.
(Further: ‘The preventive system is not business and then there is no right to health’: Petro).
“In particular, Novo Nordisk, which historically supplied more than 50% of the market, has been decreasing the units marketed and temporarily suspended the supply since the last quarter of 2024 due to manufacturing problems, without informing the estimated date of return date“The Minsalud explains.
Therefore, according to the entity, since October 2024, human insulins (crystalline and isophan) are included in the list of vital medicines not available to INVIMA.
Insulin
Istock
The Ministry of Health also mentions that crystalline human insulin is mainly used in the intra -hospital field as the first choice medication for the management of hyperglycemia. In the outpatient environment, its use has been largely replaced by analog insulins, a situation similar to that of isopan human insulin.
(Besides: Cesar Gaviria holds the Minister of Health for the system crisis).
“As a result, the demand for these medications has decreased and, due to their lower cost compared to analog insulins, the industry has shown less interest in its commercialization. However, the fact that its profitability is low, does not imply that these medications are not important for health care“, he says.
Availability of crystalline and isopane insulin to cut of July 24
– Crystalline human insulin: They have the availability for marketing 14,900 units. In addition, INVIMA authorized the import of 70,000 units under the vital medicine modality not available.
– Isopan human insulin (NPH): They have 23,000 units marketing, and INVIMA authorized the import of 80,000 units under the vital modality not available.
Portfolio
